News

Sandoz Voluntarily Recalls All Methotrexate Lots


 

Sandoz Inc. has voluntarily recalled all lots of Methotrexate Injection, after small glass flakes were found in four lots.

The glass flakes were found by Sandoz quality control, and are a result of delamination of the glass that is used to manufacture the vials, according to a statement released by Sandoz.

The manufacturer noted that lodging of the particles could lead to serious adverse events that could result in disability or death.

More information, including lot numbers, label type, and expiration date can be found on the Sandoz and Food and Drug Administration websites.

Patients should discontinue use of the product immediately.

Recommended Reading

FDA Bans Marketing of Unapproved Forms of Colchicine
MDedge Dermatology
NICE Draft Nixes Golimumab for Psoriatic Arthritis
MDedge Dermatology
EADV: Cutaneous Lupus Rapidly Progresses to SLE, New Study Finds
MDedge Dermatology
Psoriatic Arthritis Patients May Be Predisposed to Depression
MDedge Dermatology
EADV: Implant Reduced Phototoxic Attacks in Erythropoietic Protoporphyria
MDedge Dermatology
EADV: Study Points to Optimal Etanercept Regimen for Psoriasis, PsA
MDedge Dermatology
AMG 827 Trial Participants Show Improvement of Chronic Plaque Psoriasis
MDedge Dermatology
Expert Panel: Switch Methotrexate Nonresponders to Subcutaneous Form
MDedge Dermatology
EADV: Patients Often Unaware of Infliximab Infusion Risk
MDedge Dermatology
Update on Pediatric Psoriasis, Part 2: Therapeutic Management
MDedge Dermatology